 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...107108109110111112113114115116117...123124» |
- |||||||||| nofazinlimab (CS1003) / CStone Pharma
New P3 trial, Combination therapy, Metastases: CS1003-305: A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - Dec 10, 2019
P3, N=525, Not yet recruiting, Sponsor: CStone Pharmaceuticals
- Lenvima (lenvatinib) / Eisai, Merck (MSD), capecitabine / Generic mfg.
Phase I study of preoperative capecitabine and lenvatinib with external radiation therapy in locally advanced rectal adenocarcinoma. (Level 1, West Hall - Poster Board F11) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_876;
P1
The encouraging results will need to be validated in a randomized study. Clinical trial information: NCT02935309.
- PHY 906 / Kadmon, Nexavar (sorafenib) / Bayer, Amgen
A phase II randomized placebo-controlled study investigating the combination of yiv-906 and sorafenib (SORA) in HBV (+) patients (Pts) with advanced hepatocellular carcinoma (HCC). (Level 1, West Hall - Poster Board P14) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_743;
P2
Clinical trial information: NCT04000737. Research Funding: Yiviva Inc
- Association of objective response by mRECIST with better overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with systemic therapies: A systematic review and meta-analysis of randomized controlled trials. (Level 1, West Hall - Poster Board F3) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_563;
Patients achieving an objective response can expect a significantly longer OS. Research Funding: None
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
The efficacy and safety of lenvatinib in patients with intermediate-stage hepatocellular carcinoma: A nationwide multicenter study in Japan. (Level 1, West Hall - Poster Board D9) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_526;
The therapeutic strategies for intermediate-stage HCC should be discussed based on the liver function, tumor states, and treatment course about TACE. Research Funding: None
- Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Immunotherapy versus biologics as second-line therapy in advanced hepatocellular carcinoma (HCC). (Level 1, West Hall - Poster Board C14) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_511;
P1
In this study population, IO was not superior to multi-TKI as a 2nd line regimen. The late survival curve separation favoring IO might suggest a delay IO effect in a subgroup of patients.
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC). (Level 1, West Hall - Poster Board C5) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_503;
P3
This analysis also found that LEN provided benefit vs SOR for uHCC, regardless of BL liver function. The benefit of LEN may be underestimated, as more ALBI-2 pts and fewer ALBI-1 pts received LEN vs SOR.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Initial lenvatinib therapy with no prior TACE in patients with intermediate-stage hepatocellular carcinoma beyond up-to-seven criteria and Child-Pugh A liver function: A proof-of-concept study. (Level 1, West Hall - Poster Board C3) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_501;
In particular, leventinib is associated with preservation of hepatic function during treatment while TACE is associated with deterioration of hepatic function. Research Funding: None
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Subsequent anticancer procedures following first-line lenvatinib (LEN): A post hoc analysis from the phase III REFLECT study in unresectable hepatocellular carcinoma (uHCC). (Level 1, West Hall - Poster Board C1) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_499;
P3
Clinical trial information: NCT01761266. Research Funding: This study was sponsored by Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.
- Opdivo (nivolumab) / Ono Pharma, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117. (Level 1, West Hall - Poster Board B16) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_492;
P1b
Clinical trial information: NCT03418922. Research Funding: Eisai Inc., Woodcliff Lake, NJ, USA and Ono Pharmaceutical Co., Ltd
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Comparison of the frequency of adverse events requiring interventions determined by telephone follow up in hepatocellular carcinoma patients treated with sorafenib and lenvatinib. (Level 1, West Hall - Poster Board B10) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_486;
Although a great number of patients taking sorafenib had symptomatic AEs, such as HFS, early detection of the symptoms through TF contributed to prevention of treatment withdrawal on account of AEs. Research Funding: None
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
The impact of skeletal muscle loss for hepatocellular carcinoma treated with lenvatinib. (Level 1, West Hall - Poster Board A18) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_472;
However, chronological decreasing of SMI for 8 weeks was a prognostic factor of HCC patients treated with LEN. Therefore, monitoring and preventing of decreasing of skeletal muscle mass may be important.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Efficacy and safety of lenvatinib (LEN) in Korean patients (pts) with advanced hepatocellular carcinoma (aHCC): Multicenter retrospective analysis. (Level 1, West Hall - Poster Board A15) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_469;
LEN was effective and well tolerated in pts with aHCC in Korean real-life setting. Research Funding: None
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma beyond progression of sorafenib treatment: A real-world evidence and in vitro assessment with protein phosphorylation array. (Level 1, West Hall - Poster Board A10) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_464;
LEN seems more effective for HCC patients with better hepatic reserve function, or before TKI-resistance is acquired because of the partial cross-resistance to SOR. Research Funding: None
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
An open-label phase II study of lenvatinib plus pembrolizumab in patients with advanced gastric cancer (EPOC1706). (Level 1, West Hall - Poster Board E7) - Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_314;
P2
Clinical trial information: NCT03609359. Research Funding: MSD
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Stroma, Metastases: LENVAGIST: Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure (clinicaltrials.gov) - Dec 9, 2019
P2, N=74, Not yet recruiting, Sponsor: Centre Leon Berard
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
لنواتینیب (انگلیسی: Lenvatinib) با نام تجاری لِنویما یک داروی ضد سرطان است که جهت درمانِ برخی از انواع سرطان تیروئید و همچنین چند سرطان دیگر بهکار میرود #HPV #humanpapillomavirus (#HPV).@merck (Twitter) - Dec 9, 2019
- || Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal, PD(L)-1 Biomarker: Systemic Treatment Options in Hepatocellular Carcinoma. (Pubmed Central) - Dec 8, 2019
Here, we provide a comprehensive overview of the clinical trial data of systemic agents that are currently approved for advanced HCC (sorafenib, regorafenib, and nivolumab), including agents recently approved in 2018 (lenvatinib, pembrolizumab, and cabozantinib) and those with recent positive phase II/III results (ramucirumab)...The treatment of advanced HCC remains challenging and complex. The rapid developments in systemic therapy for advanced HCC should be considered when determining the best choice and sequence of treatment for patients with advanced HCC.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Clinical, Journal: Change in arterial tumor perfusion is an early biomarker of lenvatinib efficacy in patients with unresectable hepatocellular carcinoma. (Pubmed Central) - Dec 6, 2019
The rapid developments in systemic therapy for advanced HCC should be considered when determining the best choice and sequence of treatment for patients with advanced HCC. CEUS may be useful for the early prediction of tumor response to lenvatinib therapy in patients with unresectable HCC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Metastases: Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov) - Dec 4, 2019
P1, N=22, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
CEUS may be useful for the early prediction of tumor response to lenvatinib therapy in patients with unresectable HCC. N=16 --> 22
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed: KEYNOTE-146: A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors (clinicaltrials.gov) - Dec 3, 2019
P1b/2, N=360, Active, not recruiting, Sponsor: Eisai Inc.
N=16 --> 22 Recruiting --> Active, not recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Combination therapy: A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma (clinicaltrials.gov) - Dec 2, 2019
P2, N=72, Not yet recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting Trial completion date: Dec 2024 --> Dec 2022
- ||| Afinitor (everolimus) / Novartis, Opdivo (nivolumab) / Ono Pharma, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
NIVO failed badly (growth & pneumonitis ). CABO worked for a while. Currently bad QoL on Lenvima + Afinitor. So what are you saying? (Twitter) - Dec 1, 2019
- ||||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Preclinical: Thank you @TiansterZhang -found some preclinical data to support use of Lenvatinib in RCC Brain mets (Twitter) - Dec 1, 2019
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Lenvatinib+pembrolizumab (Twitter) - Nov 30, 2019
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
لنواتینیب (انگلیسی: Lenvatinib) با نام تجاری لِنویما یک داروی ضد سرطان است که جهت درمانِ برخی از انواع سرطان تیروئید و همچنین چند سرطان دیگر بهکار میرود @Merck (Twitter) - Nov 30, 2019
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Lenvatinib: A Review in Hepatocellular Carcinoma. (Pubmed Central) - Nov 29, 2019
Given its non-inferior efficacy to sorafenib and manageable tolerability profile, lenvatinib represents a long-awaited alternative option to sorafenib for the first-line systemic treatment of patients with unresectable HCC. Further clinical experience may be required to fully define the position of lenvatinib in this setting.
- | selumetinib (AZD6244) / Merck (MSD), AstraZeneca
Clinical, P2 data, Journal: Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial. (Pubmed Central) - Nov 29, 2019
The findings of this trial will be useful to healthcare professionals and patients alike to determine whether further study of this agent is warranted. It is hoped that the development of the infrastructure to deliver a multicentre trial involving molecular radiotherapy dosimetry will lead to further trials in this field.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Review, Journal: 2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer. (Pubmed Central) - Nov 29, 2019
Based on the available studies and on personal experience, the experts provided 39 recommendations aimed to improve the management of advanced RAI-R TCs. Above all of them is the indication to treat and follow these patients in a specialized setting which allows the interaction between several specialists in a multidisciplinary team.
- || Sutent (sunitinib) / Pfizer, Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal: Sorafenib and Sunitinib for the Treatment of Metastatic Thyroid Cancer of Follicular Origin: A 7-Year Single-Centre Experience. (Pubmed Central) - Nov 29, 2019
Sorafenib and sunitinib appear to be effective treatment options in delaying disease progression of patients with RAI-refractory metastatic DTC, with an acceptable safety profile. Interestingly, sunitinib appears to show some efficacy even in patients who experience disease progression on sorafenib.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE. (Pubmed Central) - Nov 29, 2019
Interestingly, sunitinib appears to show some efficacy even in patients who experience disease progression on sorafenib. No abstract available
- || Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Review, Journal, PD(L)-1 Biomarker, IO Biomarker: Systemic Treatment for Advanced Hepatocellular Carcinoma. (Pubmed Central) - Nov 29, 2019
Lenvatinib is expected to join sorafenib as a preferred first-line treatment in advanced HCC. In the second line, the treatment of choice, regorafenib, is soon expected to be accompanied by cabozantinib and ramucirumab in patients with AFP ≥400 ng/mL, whereas nivolumab and pembrolizumab present second-line alternatives in the US.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: The multiple-kinase inhibitor lenvatinib inhibits the proliferation of acute myeloid leukemia cells. (Pubmed Central) - Nov 29, 2019
Treatment of lenvatinib inhibited in vivo tumor growth of AML cells. The multiple-kinase inhibitor lenvatinib inhibits the in vitro proliferation of AML cells, and restricts the in vivo growth of AML tumors.
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial suspension, Metastases: Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Nov 29, 2019
P1, N=15, Suspended, Sponsor: Yousef Zakharia
The multiple-kinase inhibitor lenvatinib inhibits the in vitro proliferation of AML cells, and restricts the in vivo growth of AML tumors. Recruiting --> Suspended
- | Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Biomarker, Journal: Unmasking a new prognostic marker and therapeutic target from the GDNF-RET/PIT1/p14ARF/p53 pathway in acromegaly. (Pubmed Central) - Nov 27, 2019
Some of the pituitary acromegaly samples were collected in the framework of the Spanish National Registry of Acromegaly (REMAH), partially supported by an unrestricted grant from Novartis to the Spanish Endocrine Association (SEEN). CVA is also supported from a grant of Medical Research Council UK MR/M018539/1.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib. (Pubmed Central) - Nov 27, 2019
No other concomitant local or systemic risk factors for MRONJ were present. With new cancer therapies applied every year, it is important to note this novel case of lenvatinib osteonecrosis of the jaw in a patient undergoing cancer treatment.
- | fludarabine / Generic Mfg., Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: A computer-assisted discovery of novel potential anti-obesity compounds as selective carbonic anhydrase VA inhibitors. (Pubmed Central) - Nov 27, 2019
The docking analysis highlighted 12 promising best hits, biologically characterized in terms of their hCA VA inhibitory activity. Interestingly, among them, the anticancer agents fludarabine and lenvatinib and the antiepileptic rufinamide were able to selectively inhibit the enzyme activity in the micromolar range, while a pyrido-indole derivative, the homovanillic acid sulfate and the desacetyl metabolite of the antibacterial cephapirin in the nanomolar range.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Preclinical, Journal: Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines In Vitro and In Vivo. (Pubmed Central) - Nov 27, 2019
Antiproliferative effects of lenvatinib on liver cancer cells were observed in vitro and in vivo. Lenvatinib may suppress tumor formation by inhibiting angiogenesis, and via an additional direct antiproliferative effect in some liver cancer cells.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies (clinicaltrials.gov) - Nov 26, 2019
P2, N=24, Recruiting, Sponsor: NYU Langone Health
Lenvatinib may suppress tumor formation by inhibiting angiogenesis, and via an additional direct antiproliferative effect in some liver cancer cells. Trial completion date: Oct 2019 --> Nov 2020 | Trial primary completion date: Jul 2019 --> Nov 2020
- | Caprelsa (vandetanib) / Sanofi, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Exelixis
Enrollment closed, Enrollment change, Metastases: Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer (clinicaltrials.gov) - Nov 25, 2019
P2, N=6, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Trial completion date: Oct 2019 --> Nov 2020 | Trial primary completion date: Jul 2019 --> Nov 2020 Recruiting --> Active, not recruiting | N=45 --> 6
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal, Adverse events: Analyses of objective response, progression-free survival and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study. (Pubmed Central) - Nov 25, 2019
Recruiting --> Active, not recruiting | N=45 --> 6 BCLC intermediate-stage was the predictive factor affecting the ORR and PFS, and ALBI grade was good predictive factor affecting the incidence of fatigue and decreased appetite.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
I’ve been more impressed with lenvatinib in my daily practice than the REFLECT Trial would reflect. Not just a subtle response in some folks, my anecdotal experience is superior (Twitter) - Nov 23, 2019
- || Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Clinical, Journal, HEOR: Lenvatinib Versus Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-Utility Analysis. (Pubmed Central) - Nov 23, 2019
This cost-utility analysis showed that lenvatinib had a similar clinical effectiveness at a lower cost than sorafenib, indicating that lenvatinib may be a cost-saving measure in patients with unresectable HCC, in which $23,719 could be saved per patient. The introduction of a new therapeutic option for the first time in 10 years in Canada provides an important opportunity for clinicians, researchers, and health care decision-makers to explore potential modifications in recommendations and practice guidelines.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
PFS underwhelming huh-6 months? Wonder how many in investigational arm got Lenvatinib 2nd line which could help push OS if control arm gets single agent checkpoint 2nd line (inferior therapy) (Twitter) - Nov 23, 2019
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Indeed! This is indisputable. Not like the Lenvatinib vs Sorafenib data. Still a far cry from multiple myeloma... ;) but oncologists are happy about small things :) (Twitter) - Nov 22, 2019
- | Journal, Tumor Mutational Burden: Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. (Pubmed Central) - Nov 22, 2019
Genetic alterations associated with anaplastic transformation were identified. An updated schematic of thyroid cancer genetic evolution is proposed.
- || Opdivo (nivolumab) / Ono Pharma, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, Clinical, Journal, Tumor Mutational Burden, PD(L)-1 Biomarker, IO Biomarker: Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review. (Pubmed Central) - Nov 22, 2019
In this case, the patient achieved an excellent radiological and symptomatic response after receiving nivolumab plus lenvatinib combination therapy. Patients suffering from cholangiocarcinoma with dMMR status and a high tumor mutation burden (TMB) may have a consistent eutherapeutic effect with anti-PD-1-directed treatment.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Phase 3 LEAP-003: first-line (1L) Pembrolizumab (pembro) + Lenvatinib (len) in patients (pts) with advanced melanoma (MEL) () - Nov 21, 2019 - Abstract #SMR2019SMR_149;
P3
AEs (graded per NCI CTCAE v4.0) will be assessed for ≤ 90 d. Dual primary end points: PFS (by BICR per modified RECIST v1.1) (max target lesions: 10; 5 per organ) and OS. Key secondary end points: ORR, DOR (both by BICR per modified RECIST v1.1), and safety.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Surgery, Metastases: Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery (clinicaltrials.gov) - Nov 21, 2019
P2, N=3, Active, not recruiting, Sponsor: Mayo Clinic
Key secondary end points: ORR, DOR (both by BICR per modified RECIST v1.1), and safety. Trial completion date: Feb 2020 --> Dec 2020 | Trial primary completion date: Aug 2019 --> Dec 2020